Leadership Team

Leadership Team

Our multidisciplinary Team, led by professionals with a long track record in drug development and management, relies on highly skilled personnel with unique competence in developing integrated solutions.

  • Alex Zwyer, MBA

    Chief Executive Officer & Co-Founder

    A co-founder of the company with extensive operational, C-level pharmaceutical experience. He served as Chief Operating Officer at Viforpharma AG, a specialty company focusing on Nephrology where he was globally responsible for marketing and sales, business development, and regulatory and medical affairs. He was named ‘Healthcare CEO of the Year, Switzerland’ in 2018 by Business Worldwide.

  • Sandy Eisen, MD

    Interim Chief Medical Officer(1)

    CMO at TEVA Europe with overarching responsibility for all medical affairs, clinical development and drug safety issues. Former U.K./EU regulator at MHRA and EMEA, from 2005 to 2011, served in a variety of roles at Teva Pharmaceuticals, including working as Chief Medical Officer for Teva Pharmaceuticals Europe from 2006 to 2011; medical degree from Cambridge University U.K.

  • Robert Dickey IV, MBA

    Interim Chief Financial Officer(1)

    25+ years of experience as a life sciences CFO in private and publicly- traded companies, across all stages of development. His expertise includes public and private financings, M&A, partnering/licensing and managing company’s finance and accounting functions, as well as interactions with Boards, VCs, shareholders and W all Street.

  • Mehdi Tafti, PhD

    Chief Scientific Officer(2)

    Active for 35 years in the field of sleep research and sleep medicine, he is one of the world-leading pharmacologists in narcolepsy, and has worked with both human and narcoleptic dogs. He is also one of the few in the world with a dual expertise in the basic sleep research in animal models, and pharmacology and molecular genetics of sleep disorders in humans. Dr. Tafti has served as a full-time professor in the Faculty of Biology and Medicine of the University of Lausanne since 2011.

  • Silvia Panigone, PhD.

    Chief Operating Officer(2)

    Track record in complex project management; former positions include: Global Project Manager in Quintiles for phase II/III trials in the US/EU and Asia, managing large teams including Regulatory, CMC and pharmacology full P&L responsibilities. Executive position in R&D in Bracco Diagnostics, Managing Director at I-Bankers Direct, Investment Director at BSI Healthcapital, a VC firm focused on life sciences. Ph.D. in Molecular Oncology from National Cancer Institute, Milan and a Master in Finance - Management of Economical Resources from SDA Bocconi, Milan, Italy.

  • Hervé Girsault, MBA

    Interim Chief Business Officer(1)

    Experienced C-level pharma/biotech executive, former positions include: Global Head M&A/BD Novartis Consumer Health, Head of Novartis Pharma Out-Licensing & Partnering; CBO of PIQUR Therapeutics AG (Basel); CEO, Synarc Inc. (now BioClinica Inc.) (San Francisco, CA); CEO Novartis Consumer Health, Benelux; CEO Gerber Products Company (France).

  • Geert Mayer, MD

    Chief Development Officer(2)

    A former principal investigator for JAZZ Pharmaceuticals in Germany. Member of the board of the German Sleep Society since 1996 and served as President of the society from 2006 to 2011. He has served as a professor in the Department of Psychiatry and later in the Department of Neurology at Philipps University of Marburg.

(1) Currently engaged as consultant / strategic advisor
(2) Expected to become an executive officer in the named role immediately after the completion of this offering